Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.

Total Cash From Operating Activities Chart for Amneal Pharmaceuticals, Inc. Class A Common Stock

Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) operating cash flow for FY2025 was USD 340.0M, a 15.2% change from FY2024. Amneal Pharmaceuticals, Inc. Class A Common Stock's operating cash flow grew from USD 112.3M in 2014 to USD 340.0M in 2025 (202.9% over 11 years). Operating cash flow compound annual growth rate: 5-year CAGR of -2.1%, 10-year CAGR of 12.5%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.